B · Normal
[Bori Pharmaceuticals: BGM0504 tablets received drug clinical trial approval notice] On October 12, Borui Pharmaceuticals (688166.SH) announced that the company's wholly-owned subsidiary Borui Pharmaceuticals recently received the "Drug Clinical Trial Approval Notice" issued by the State Food and Drug Administration, agreeing to conduct clinical trials of BGM0504 tablets in adult patients with type 2 diabetes. BGM0504 is a dual agonist of GLP-1 and GIP receptors independently developed by the company. No similar target in its oral dosage form has been approved for marketing in the world.
A-share announcement express 🕐 2026-10-12 20:01
#clinical trial #A-share announcement express
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Fenghua Hi-Tech: The controlling shareholder plans to reduce its holdings by no 10-12 20:44 [2 consecutive Jishi Media: AI micro-short drama business has not yet generated 10-12 20:42 [Yantian Port: Plans to invest 3.788 billion yuan in the construction of the fir 10-12 20:30 [2-Link Ciwen Media: The AIGC platform is still under construction and related p 10-12 20:29 [Rongfeng Holdings: The controlling shareholder will be changed to Guangzhou Xin 10-12 20:27 [Oke Shares: Termination of plans to issue shares and payment of cash to purchas 10-12 20:23

Comments

0/500
Captcha (click to refresh)
No comments yet